selected publications

• article

  • Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial.  The Lancet Rheumatology.  3:e122-e130. 2021-01-01
  • Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.  Arthritis and Rheumatism.  64:2328-2337. 2012-01-01